Cognetivity Neurosciences Ltd. announced that it has released an updated version of its tool, CognICATM. CognICA is a unique platform for the assessment and monitoring of brain health: powered by artificial intelligence (AI), FDA-registered and CE-marked, and commercially deployed in North America, East and Southeast Asia, the Middle East, and the UK's National Health Service (NHS). The company's technology uses AI and machine learning (ML) techniques to help detect the earliest signs of cognitive impairment by providing a fast, sensitive and objective measure of brain function.

This enables CognICATM to facilitate the early identification of individuals with brain health issues, at a time when interventions are most effective, as well as supporting their long-term treatment management and monitoring. Crucially, as a fundamentally AI and ML-based tool, CognICA can be continually expanded and enhanced over time, trained on more data from an increasing number of global deployments to build increasingly refined, disease-specific models. In the case of Alzheimer's disease, for example, the company already holds a patent covering the use of an AI-based system to estimate levels of core biomarkers of neurodegeneration in the brain, such as amyloid (A) protein.

The tool is tablet-based, self-administered and independent of language and education biases, thereby making it highly effective for comprehensive, scaled screening programs in all geographies. Among a range of improvements, the latest version of CognICA includes local data storage functionality, facilitating deployment in an expanded range of territories and thus enlarging the potential market for the technology. It also permits unlimited scaling, ensuring that users benefit from a rapid, efficient experience regardless of user load.